Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a license and distribution agreement with CSL Seqirus (ASX:CSL) for the exclusive rights to commercialize NEXLETOL ® (bempedoic ...

Both the Finnish and the U.S. bird flu vaccines are made by CSL Seqirus but are different vaccines. In the summer, U.S.

As one of the world's largest manufacturers of influenza vaccines, CSL Seqirus is on the front lines in the fight against avian influenza. In fact, the federal government's Biomedical Advanced ...

Following similar deals in countries like the United States and the U.K., Canada is bolstering its stockpile of bird flu ...

CSL Seqirus has agreed to provide 665,000 doses of a bird flu vaccine to the European Commission as part of the EU’s efforts to prepare for a potential outbreak of the disease, with an option to ...

The contract covers more than 5 million doses of a CSL Seqirus H5 influenza shot, according to a government statement, which said the vaccines would be manufactured by the company's UK subsidiary.

In other avian flu developments, tests at the US Department of Agriculture (USDA) have confirmed the H5N1 strain in rats for ...

Australian biopharmaceutical company CSL said on Tuesday that falling immunisation rates in the U.S., its largest market, weighed on its vaccine sales and first-half profit growth, sending its shares ...

Seqirus is now the world’s second largest influenza vaccine business, only behind Sanofi, and has the only FDA approved cell-based influenza vaccine, Flucelvax. Seqirus is well-positioned for ...

"The incidence of influenza and hospitalisation rates are ... The revenue of CSL Seqirus in the first half of the 2025 financial year was 15% below analysts' forecasts for the unit and also ...